We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics

News   Dec 18, 2014

 
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
 
 
 

RELATED ARTICLES

Doctors Rely on More Than Just Data During a Diagnosis

News

Computer scientists examine how a doctor’s “gut feeling” influences how many tests they order for patients

READ MORE

Working Together Helps Phage Overcome CRISPR

News

Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.

READ MORE

Novel ALS Therapy in Human Clinical Trials

News

A phase one/two clinical trial has launched to investigate whether a drug could benefit people with ALS whose disease is caused by mutations in a gene called SOD1

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE